vs
Commercial Bancgroup, Inc.（CBK）与ROCKWELL MEDICAL, INC.（RMTI）财务数据对比。点击上方公司名可切换其他公司
Commercial Bancgroup, Inc.的季度营收约是ROCKWELL MEDICAL, INC.的1.3倍（$23.1M vs $18.3M），Commercial Bancgroup, Inc.净利率更高（41.3% vs -3.0%，领先44.3%）
Commercial Bancgroup, Inc.是美国的一家区域性银行控股企业，为个人消费者、中小微企业及本地机构客户提供全品类零售与商业银行业务，核心服务涵盖存款账户、信贷产品、财富管理及定制化金融咨询方案。
罗克韦尔医疗成立于1996年，总部位于美国密歇根州威克瑟姆，是一家上市制药企业，核心业务聚焦于终末期肾病与慢性肾病相关治疗方案的研发与商业化推广。
CBK vs RMTI — 直观对比
营收规模更大
CBK
是对方的1.3倍
$18.3M
净利率更高
CBK
高出44.3%
-3.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.1M | $18.3M |
| 净利润 | $9.5M | $-554.0K |
| 毛利率 | — | 21.1% |
| 营业利润率 | — | -2.2% |
| 净利率 | 41.3% | -3.0% |
| 营收同比 | — | -25.6% |
| 净利润同比 | 9.7% | 26.7% |
| 每股收益（稀释后） | $0.69 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBKRMTI
| Q1 26 | $23.1M | — | ||
| Q4 25 | $23.5M | $18.3M | ||
| Q3 25 | $22.8M | $15.9M | ||
| Q2 25 | — | $16.1M | ||
| Q1 25 | — | $18.9M | ||
| Q4 24 | — | $24.7M | ||
| Q3 24 | — | $28.3M | ||
| Q2 24 | — | $25.8M |
净利润CBKRMTI
| Q1 26 | $9.5M | — | ||
| Q4 25 | $9.9M | $-554.0K | ||
| Q3 25 | $9.5M | $-1.8M | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-1.5M | ||
| Q4 24 | — | $-756.0K | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $343.0K |
毛利率CBKRMTI
| Q1 26 | — | — | ||
| Q4 25 | — | 21.1% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 16.1% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | — | 22.0% | ||
| Q2 24 | — | 17.6% |
营业利润率CBKRMTI
| Q1 26 | — | — | ||
| Q4 25 | — | -2.2% | ||
| Q3 25 | 53.8% | -9.9% | ||
| Q2 25 | — | -8.4% | ||
| Q1 25 | — | -7.2% | ||
| Q4 24 | — | -2.1% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 2.0% |
净利率CBKRMTI
| Q1 26 | 41.3% | — | ||
| Q4 25 | 42.2% | -3.0% | ||
| Q3 25 | 41.4% | -11.0% | ||
| Q2 25 | — | -9.3% | ||
| Q1 25 | — | -8.0% | ||
| Q4 24 | — | -3.1% | ||
| Q3 24 | — | 5.9% | ||
| Q2 24 | — | 1.3% |
每股收益（稀释后）CBKRMTI
| Q1 26 | $0.69 | — | ||
| Q4 25 | $0.72 | $-0.01 | ||
| Q3 25 | $0.77 | $-0.05 | ||
| Q2 25 | — | $-0.05 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | — | $0.04 | ||
| Q2 24 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $10.7M |
| 总债务越低越好 | $118.2M | — |
| 股东权益账面价值 | — | $37.0M |
| 总资产 | $2.3B | $57.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CBKRMTI
| Q1 26 | — | — | ||
| Q4 25 | — | $10.7M | ||
| Q3 25 | $154.8M | $13.6M | ||
| Q2 25 | — | $12.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $15.7M | ||
| Q3 24 | — | $12.3M | ||
| Q2 24 | — | $11.9M |
总债务CBKRMTI
| Q1 26 | $118.2M | — | ||
| Q4 25 | $166.8M | — | ||
| Q3 25 | $100.1M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CBKRMTI
| Q1 26 | — | — | ||
| Q4 25 | — | $37.0M | ||
| Q3 25 | $245.2M | $37.0M | ||
| Q2 25 | — | $30.4M | ||
| Q1 25 | — | $31.5M | ||
| Q4 24 | — | $32.6M | ||
| Q3 24 | — | $29.1M | ||
| Q2 24 | — | $23.5M |
总资产CBKRMTI
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $57.1M | ||
| Q3 25 | $2.2B | $57.5M | ||
| Q2 25 | — | $52.6M | ||
| Q1 25 | — | $54.0M | ||
| Q4 24 | — | $59.2M | ||
| Q3 24 | — | $57.1M | ||
| Q2 24 | — | $53.0M |
负债/权益比CBKRMTI
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $2.3M |
| 自由现金流经营现金流 - 资本支出 | — | $2.2M |
| 自由现金流率自由现金流/营收 | — | 12.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.2M |
8季度趋势，按日历期对齐
经营现金流CBKRMTI
| Q1 26 | — | — | ||
| Q4 25 | — | $2.3M | ||
| Q3 25 | $28.0M | $-1.3M | ||
| Q2 25 | — | $1.8M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | $865.0K | ||
| Q3 24 | — | $4.3M | ||
| Q2 24 | — | $1.4M |
自由现金流CBKRMTI
| Q1 26 | — | — | ||
| Q4 25 | — | $2.2M | ||
| Q3 25 | $26.5M | $-1.5M | ||
| Q2 25 | — | $1.7M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | $470.0K | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $1.2M |
自由现金流率CBKRMTI
| Q1 26 | — | — | ||
| Q4 25 | — | 12.0% | ||
| Q3 25 | 115.8% | -9.6% | ||
| Q2 25 | — | 10.5% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 4.5% |
资本支出强度CBKRMTI
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | 6.7% | 1.4% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 1.1% |
现金转化率CBKRMTI
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.96× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 4.20× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBK
| Net Interest Income | $20.5M | 89% |
| Noninterest Income | $2.6M | 11% |
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
